scholarly journals The DRY motif at work: the P2Y12 receptor case

2014 ◽  
Vol 12 (5) ◽  
pp. 713-715 ◽  
Author(s):  
G. E. Rovati ◽  
V. Capra
Keyword(s):  
P2y12 Receptor ◽  
Dry Motif

scholarly journals Central role of the P2Y12 receptor in platelet activation

2004 ◽  
Vol 113 (3) ◽  
pp. 340-345 ◽  
Author(s):  
Robert T. Dorsam ◽  
Satya P. Kunapuli
Keyword(s):  
Platelet Activation ◽  
P2y12 Receptor

The potency of selatogrel, a reversible antagonist of the P2Y12 receptor, is affected by calcium concentration

Platelets ◽  
2021 ◽  
pp. 1-10
Author(s):  
Martine Baumann ◽  
Benoît Lack ◽  
Isabelle Guillaumat ◽  
Mark J. Murphy ◽  
Markus A. Riederer
Keyword(s):  
Calcium Concentration ◽  
P2y12 Receptor

P2Y12 Receptor Inhibitors in ACS Management with or without ST-segment Elevation

2021 ◽  
Vol 10 (3) ◽  
pp. 137-140
Author(s):  
Abdulrahman Mousa Aljohani ◽  
Moaath Saleh Aljuhani ◽  
Khalid Dhaifallah Almalki ◽  
Ghassan Abdullah Alhazmi ◽  
Anas Mohammed Ghaith ◽  
...  
Keyword(s):  
P2y12 Receptor ◽  
St Segment Elevation ◽  
St Segment

A Prospective, Randomized, Open-Label, Blinded, Endpoint Study Exploring Platelet Response to Half-Dose Prasugrel and Ticagrelor in Patients with the Acute Coronary Syndrome: HOPE-TAILOR Study

Cardiology ◽  
2017 ◽  
Vol 138 (4) ◽  
pp. 201-206 ◽  
Author(s):  
Cai De Jin ◽  
Moo Hyun Kim ◽  
Junghee Bang ◽  
Victor Serebruany
Keyword(s):  
Acute Coronary Syndrome ◽  
Platelet Reactivity ◽  
Academic Research ◽  
P2y12 Receptor ◽  
Drug Eluting Stent ◽  
Platelet Response ◽  
Open Label ◽  
Korean Patients ◽  
Coronary Syndrome ◽  
Half Dose

Background: The optimal dosing of novel oral P2Y12 receptor platelet inhibitors such as prasugrel or ticagrelor is unclear and especially challenging in East Asians. We hypothesize that half-dose prasugrel and ticagrelor may be sufficient for long-term maintenance management in Korean patients with the acute coronary syndrome (ACS) compared with conventional dosages. Design: HOPE-TAILOR (Half Dose of Prasugrel and Ticagrelor in Platelet Response after Acute Coronary Syndromes) is a prospective, randomized, open-label, blinded, endpoint (PROBE) single-center, clinical trial. A total of 100 patients with ACS undergoing drug-eluting stent implantation will be randomly assigned to prasugrel, ticagrelor, or clopidogrel, and the patients in each treatment group will receive 1-month therapy with 100 mg q.d. aspirin plus prasugrel 10 mg q.d., ticagrelor 90 mg b.i.d., or clopidogrel 75 mg q.d., followed by half-dose prasugrel 5 mg q.d. or ticagrelor 45 mg b.i.d. for maintenance treatment but without clopidogrel dose reduction. The primary endpoint will be optimal platelet reactivity 3 months after coronary intervention, defined by VerifyNow Analyzer (PRU: 85-208) and vasodilator-stimulated phosphoprotein P2Y12 flow cytometry assay (platelet reactivity indices: 16-50%). Clinical outcomes will also be assessed, including major efficacy (composite of cardiac death, nonfatal myocardial infarction, repeat revascularization, or stroke) and safety (bleeding ≥2 according to the Bleeding Academic Research Consortium). Conclusion: HOPE-TAILOR is a prospective, randomized, open-label, blinded, endpoint study to explore the efficacy and safety of novel P2Y12 receptor inhibitors administered orally at half the dose in Korean patients with ACS. The results will be available late in 2017.

scholarly journals TCT-112 Pretreatment with P2Y12 receptor antagonists is not associated with improved patency of infarct related-artery in NSTEMI – A report from SCAAR

2016 ◽  
Vol 68 (18) ◽  
pp. B45
Author(s):  
Christian Dworeck ◽  
Inger Haraldsson ◽  
Oscar Angeras ◽  
Jacob Odenstedt ◽  
Dan Ioanes ◽  
...  
Keyword(s):  
P2y12 Receptor ◽  
Receptor Antagonists ◽  
Infarct Related Artery

Repeat oral dosing of prasugrel, a novel P2Y12 receptor inhibitor, results in cumulative and potent antiplatelet and antithrombotic activity in several animal species

2008 ◽  
Vol 579 (1-3) ◽  
pp. 276-282 ◽  
Author(s):  
Yoichi Niitsu ◽  
Atsuhiro Sugidachi ◽  
Taketoshi Ogawa ◽  
Joseph A. Jakubowski ◽  
Masami Hashimoto ◽  
...  
Keyword(s):  
Animal Species ◽  
P2y12 Receptor ◽  
Antithrombotic Activity ◽  
Oral Dosing ◽  
Receptor Inhibitor
Sign in / Sign up

Export Citation Format

Share Document